Literature DB >> 25161171

Efavirenz induces neuronal autophagy and mitochondrial alterations.

Phillip R Purnell1, Howard S Fox2.   

Abstract

Efavirenz (EFV) is a non-nucleoside reverse-transcriptase inhibitor in wide use for the treatment of human immunodeficiency virus infection. Although EFV is generally well tolerated, neuropsychiatric toxicity has been well documented. The toxic effects of EFV in hepatocytes and keratinocytes have been linked to mitochondrial perturbations and changes in autophagy. Here, we studied the effect of EFV on mitochondria and autophagy in neuronal cell lines and primary neurons. In SH-SY5Y cells, EFV induced a drop in ATP production, which coincided with increased autophagy, mitochondrial fragmentation, and mitochondrial depolarization. EFV-induced mitophagy was also detected by colocalization of mitochondria and autophagosomes and use of an outer mitochondrial membrane tandem fluorescent vector. Pharmacologic inhibition of autophagy with 3-methyladenine increased the cytotoxic effect of EFV, suggesting that autophagy promotes cell survival. EFV also reduces ATP production in primary neurons, induces autophagy, and changes mitochondrial morphology. Overall, EFV is able to acutely induce autophagy and mitochondrial changes in neurons. These changes may be involved in the mechanism leading to central nervous system toxicity observed in clinical EFV use.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25161171      PMCID: PMC4201278          DOI: 10.1124/jpet.114.217869

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  46 in total

Review 1.  Neuronal toxicity of efavirenz: a systematic review.

Authors:  Eric H Decloedt; Gary Maartens
Journal:  Expert Opin Drug Saf       Date:  2013-07-29       Impact factor: 4.250

2.  Assessment of mitochondrial toxicity in HepG2 cells cultured in high-glucose- or galactose-containing media.

Authors:  Rachel Swiss; Yvonne Will
Journal:  Curr Protoc Toxicol       Date:  2011-08

3.  Mitochondrial membrane potential monitored by JC-1 dye.

Authors:  M Reers; S T Smiley; C Mottola-Hartshorn; A Chen; M Lin; L B Chen
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

4.  Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy.

Authors:  Nadezda Apostolova; Leysa J Gomez-Sucerquia; Anna Gortat; Ana Blas-Garcia; Juan V Esplugues
Journal:  Hepatology       Date:  2011-08-02       Impact factor: 17.425

Review 5.  The end of AIDS: HIV infection as a chronic disease.

Authors:  Steven G Deeks; Sharon R Lewin; Diane V Havlir
Journal:  Lancet       Date:  2013-10-23       Impact factor: 79.321

6.  Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells.

Authors:  Ana Blas-García; Nadezda Apostolova; Daniel Ballesteros; Daniel Monleón; Jose M Morales; Milagros Rocha; Victor M Victor; Juan V Esplugues
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

Review 7.  The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression.

Authors:  Rodrigo Diaz-Ruiz; Michel Rigoulet; Anne Devin
Journal:  Biochim Biophys Acta       Date:  2010-09-08

Review 8.  Mitochondrial quality control: a matter of life and death for neurons.

Authors:  Elena I Rugarli; Thomas Langer
Journal:  EMBO J       Date:  2012-02-21       Impact factor: 11.598

Review 9.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

10.  Neuronal autophagy: a housekeeper or a fighter in neuronal cell survival?

Authors:  Jin-A Lee
Journal:  Exp Neurobiol       Date:  2012-02-28       Impact factor: 3.261

View more
  25 in total

Review 1.  HIV-1 infection alters energy metabolism in the brain: Contributions to HIV-associated neurocognitive disorders.

Authors:  Bianca Cotto; Kalimuthusamy Natarajanseenivasan; Dianne Langford
Journal:  Prog Neurobiol       Date:  2019-05-18       Impact factor: 11.685

Review 2.  An Overview of Human Immunodeficiency Virus Type 1-Associated Common Neurological Complications: Does Aging Pose a Challenge?

Authors:  Anantha Ram Nookala; Joy Mitra; Nitish S Chaudhari; Muralidhar L Hegde; Anil Kumar
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage.

Authors:  Ana B Sanchez; Giuseppe P Varano; Cyrus M de Rozieres; Ricky Maung; Irene C Catalan; Cari C Dowling; Natalia E Sejbuk; Melanie M Hoefer; Marcus Kaul
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

4.  Efavirenz as a potential drug for the treatment of triple-negative breast cancers.

Authors:  P-T Chiou; S Ohms; P G Board; J E Dahlstrom; D Rangasamy; M G Casarotto
Journal:  Clin Transl Oncol       Date:  2020-06-21       Impact factor: 3.405

5.  Dysregulation of Endoplasmic Reticulum Stress and Autophagic Responses by the Antiretroviral Drug Efavirenz.

Authors:  Luc Bertrand; Michal Toborek
Journal:  Mol Pharmacol       Date:  2015-05-18       Impact factor: 4.436

Review 6.  Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System.

Authors:  Luc Bertrand; Madhavan Nair; Michal Toborek
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 7.  Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.

Authors:  Ankit Shah; Mohitkumar R Gangwani; Nitish S Chaudhari; Alexy Glazyrin; Hari K Bhat; Anil Kumar
Journal:  Neurotox Res       Date:  2016-06-30       Impact factor: 3.911

8.  Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.

Authors:  Kelly L Stauch; Katy Emanuel; Benjamin G Lamberty; Brenda Morsey; Howard S Fox
Journal:  J Neurovirol       Date:  2017-09-11       Impact factor: 2.643

Review 9.  Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury.

Authors:  Nina Y Yuan; Marcus Kaul
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-06       Impact factor: 4.147

10.  Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression.

Authors:  Leah H Rubin; Pauline M Maki; Gayle Springer; Lorie Benning; Kathryn Anastos; Deborah Gustafson; Maria C Villacres; Xiong Jiang; Adaora A Adimora; Drenna Waldrop-Valverde; David E Vance; Hector Bolivar; Christine Alden; Eileen M Martin; Victor G Valcour
Journal:  Neurology       Date:  2017-09-13       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.